Lumateperone Tosylate Drug Asset Due Diligence Report 2026

This Lumateperone Tosylate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Lumateperone Tosylate can convert its Small molecule drug profile and 5-HT2A receptor x D2 receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Lumateperone Tosylate (query alias: lumateperone)
Modality / target	Small molecule drug; 5-HT2A receptor x D2 receptor; 5-HT2A receptor antagonists, D2 receptor antagonists
Highest global status	Approved
Originator	Bristol Myers Squibb Co.
Active developers	Shandong Lutai Huanzhong Pharmaceutical Co. Ltd., Intra-Cellular Therapies, Inc., Qilu Pharmaceutical Co., Ltd.

The MCP disease footprint includes Bipolar I disorder, Bipolar II disorder, Depressive Disorder. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07676669	Phase 4	Not yet recruiting	140	Change in Montgomery-Åsberg Depression Rating Scale (MADRS) score
NCT07369115	Phase 4	Not yet recruiting	50	The primary efficacy endpoint is the absolute change in Montgomery-Åsberg Depression Rating Scale (MADRS) total scores from Baseline to end of Treatment visit at Week 6 in subjects on ADT plus Lumateperone or matching placebo.
NCT07699445	Phase 4	Not yet recruiting	25	MADRS

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Double-Blind, Placebo-Controlled Study of Caplyta in the Treatment of Borderline Personality Disorder

Phase 2; n=60; evaluation: not stated. Reported fields: Change in Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) Total Score(Mean) = -6.87 Score on a scale (Standard Deviation, 6.8); -; Change in Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) Total Score(Mean) = -9.07 Score on a scale (Standard Deviation, 4.06)

An Open-label Multiple Oral Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lumateperone in Patients, Ages 13 to 17 Years, Diagnosed With Schizophrenia or Schizoaffective Disorder

Phase 1; n=26; evaluation: not stated. Reported fields: -; Day 1(Mean) = 19.12 ng/mL (Standard Deviation, 11.21); -

An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Phase 3; n=812; evaluation: not stated. Reported fields: The Number and Percentage of Patients Reporting Treatment Emergent Adverse Events = 548 Participants ; -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Lumateperone Tosylate addresses Bipolar I disorder, Bipolar II disorder, Depressive Disorder. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-01-13	Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership	Phase 2	US$14,600.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Lumateperone intermediate and preparation method therefor”. The milestone feed surfaced a patent-application signal described as “Lumateperone intermediate salts, processes for their preparation and lumateperone intermediate obtained therefrom”. The milestone feed surfaced a patent-application signal described as “Lumateperone and analogues, as 5-HT2a or 5-HT2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO